Graft Polymer d.o.o. was established in 2017 by a group of polymer technology experts and venture capitalists. Graft Polymer’s core business comprises polymer modification and the development of drug delivery systems. The Group is a highly innovative business with strong intellectual property and several patent applications.

Our motto, “COMBINE INCOMPATIBLE,”  defines the nature of our business: to create polymer modifiers to combine immiscible and incompatible components of polymer alloys to achieve cost-effective polymers with high mechanical characteristics, chemical resistance, and fire-retardant properties.

Graft Polymer offers bespoke, adapted, and tailored products for customer requests.

Our market-leading expertise and industry knowledge offer the best solution for your application requirements.

Graft Polymer’s innovative nano-methods of manufacturing technologies can offer a tailored solution or multi-composite structure that can deliver performance, functionality, and economic advantages.

In 2020, the Group launched a new division named GraftBio to develop IP for Bio/Pharma applications. This includes Bio Supplements and drug delivery systems to support and provide solutions to the market, which had been heavily impacted by the COVID-19 pandemic.

GraftBio has been granted a Hazard Analysis and Critical Control Point (“HACCP”) certificate at the group’s Research and Development facility in Slovenia. The grant of this certificate is a major milestone for Graft Polymer, which will enable us to enter the Business-to-Consumer market.

We welcome any offers from distributors and strategic partners to create new business opportunities. To get in touch, please visit our site’s ‘Contact Us’ page.